Previous retrospective cohort studies identified potential predictive value of PBRM1, BAP1 and TP53 mutations in primary tumour tissue from ccRCC patients that received treatment with first‐line tyrosine kinase inhibitors [28, 29]. The gene discussed is TP53; the disease is nonpapillary renal cell carcinoma.